Ethris Announces Approval of Phase I Clinical Study for ETH47, a First-in-Class Inhaled mRNA for Respiratory Viral Infections

MUNICH, Germany, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced that it has received approval from the United

Related Keywords

Germany ,United Kingdom ,Munich ,Bayern ,German ,Philipp Schreppel ,Carsten Rudolph ,Ethris Gmb ,Lifesci Communications ,Regulatory Agency ,Clinical Trial Authorization ,Stabilized Non Immunogenic ,Stabilized Nanoparticle ,